Best response after treatment
| Response status, n (%) . | Sequential (n = 118) . | Alternating (n = 115) . | P . |
|---|---|---|---|
| Overall response rate (greater than or equal to PR) | 90 (76) | 92 (80) | .7 |
| sCR | 20 (17) | 20 (17) | 1.0 |
| CR | 29 (25) | 26 (23) | .8 |
| Very good PR | 25 (21) | 26 (24) | .5 |
| PR | 16 (14) | 20 (16) | .6 |
| Stable disease | 4 (3) | 3 (3) | .8 |
| Progressive disease | 16 (14) | 16 (14) | 1.0 |
| Response status, n (%) . | Sequential (n = 118) . | Alternating (n = 115) . | P . |
|---|---|---|---|
| Overall response rate (greater than or equal to PR) | 90 (76) | 92 (80) | .7 |
| sCR | 20 (17) | 20 (17) | 1.0 |
| CR | 29 (25) | 26 (23) | .8 |
| Very good PR | 25 (21) | 26 (24) | .5 |
| PR | 16 (14) | 20 (16) | .6 |
| Stable disease | 4 (3) | 3 (3) | .8 |
| Progressive disease | 16 (14) | 16 (14) | 1.0 |
The best response after treatment is according to International Myeloma Working Group criteria. Eight patients in the sequential arm and 4 patients in the alternating arm were not evaluable for response because they discontinued early before completing the first cycle.